Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 mars 2024 07h00 HE
|
Iterum Therapeutics PLC
--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN,...
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
21 mars 2024 16h30 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
15 mars 2024 08h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral...
Iterum Therapeutics Provides Business Update
06 mars 2024 08h00 HE
|
Iterum Therapeutics PLC
Resubmission of NDA is On Track for First Half of Q2 24 Extended Cash Runway into 2025 DUBLIN, Ireland and CHICAGO, March 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM)...
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
04 déc. 2023 08h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
14 nov. 2023 07h00 HE
|
Iterum Therapeutics PLC
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
07 nov. 2023 08h30 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
24 oct. 2023 08h00 HE
|
Iterum Therapeutics PLC
– Topline Data Expected in Early Q1 2024 – – NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM)...
Iterum Therapeutics to Present Data at IDWeek 2023
12 oct. 2023 09h15 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
11 août 2023 07h00 HE
|
Iterum Therapeutics PLC
--Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ----Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...